Gary Francis, MD
Cardiovascular Disease · Mpls, MNNPI 1679666317
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Novartis at 45.7% of the total. Reporting peaked in 2019 at $18,146 and has fallen 84.6% since, to $2,786 in 2022.
Across 14 payments — averaging $2075.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$13K
- Sanofi US Services Inc.$12K
- Novartis Pharma AG$2K
- Merck$2K
- AbbVie$14
Across 15 payments — averaging $2469.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$37K
What the payments were for
- Consulting fees$15,80654%
- Speaking & faculty fees$12,30442%
- Travel & lodging$8763%
- Food & beverage$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $13,266 |
| Sanofi US Services Inc. | 1 | $12,304 |
| Novartis Pharma AG | 6 | $1,906 |
| Merck | 1 | $1,560 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOTAGLIFLOZIN$12,304
- ENTRESTO$2,772
- LCZ696D_ENTRESTO_CARDIOVASCULAR$1,782
- MK-1242$1,560
How this compares
$29,050 in reported general payments places this provider in the 80th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Mpls
- Jeffrey ChambersMinneapolis$3.2M
- Srijoy MahapatraRochester$1.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Charanjit RihalRochester$478K
- Amir LermanRochester$465K
- Nedaa SkeikMinneapolis$453K
- Joao CavalcanteMinneapolis$384K
- Inderjit AnandMinneapolis$384K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.